Accéder au contenu
Merck

1287008

USP

Furosemide

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Formule empirique (notation de Hill) :
C12H11ClN2O5S
Numéro CAS:
Poids moléculaire :
330.74
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Furosemide, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

SMILES string

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI key

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

furosemide

manufacturer/tradename

USP

mp

220 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... SLC12A1(6557)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Furosemide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Furosemide Injection
  • Furosemide Oral Solution
  • Furosemide Tablets

Biochem/physiol Actions

Inhibits ion co-transport in the kidney.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Adam D DeVore et al.
European journal of heart failure, 17(3), 340-346 (2015-01-27)
Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these factors. We analysed data
Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after
Hannah Zacharias et al.
Palliative medicine, 25(6), 658-663 (2011-03-15)
Patients with advanced chronic heart failure (CHF) can experience 'revolving door' admissions, often for parenteral diuretics, when time at home is precious. Home intravenous diuretic services are patchy. This retrospective review describes 43 consecutive episodes of continuous subcutaneous infusion of
Susan B LeGrand et al.
Annals of internal medicine, 149(4), 259-263 (2008-08-20)
Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in
Daryl W Hochman
Epilepsia, 53 Suppl 1, 18-25 (2012-05-25)
Treatments that modulate the size of the extracellular space (ECS) also block epileptiform activity in adult brain tissue. This includes the loop diuretics furosemide and bumetanide, and alterations of the osmolarity of the ECS. These treatments block epileptiform activity in

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique